If the VitD drug and the growth hormone drug get approved. Plus they have a decent rollout of 4KScore. We could be looking at a company selling maybe $8B a year and netting something like $4B profits. With 400M shares, the earnings would be around $10 a share and PE of 18, this could be a $180 a share stock. That sound about right? Maybe dreaming, but these are realistic numbers on approval. Maybe even conservative. These insiders are buying for a reason.